Pascal Chastagner

5.5k total citations
161 papers, 3.5k citations indexed

About

Pascal Chastagner is a scholar working on Molecular Biology, Genetics and Neurology. According to data from OpenAlex, Pascal Chastagner has authored 161 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 49 papers in Genetics and 49 papers in Neurology. Recurrent topics in Pascal Chastagner's work include Glioma Diagnosis and Treatment (47 papers), Neuroblastoma Research and Treatments (47 papers) and Childhood Cancer Survivors' Quality of Life (34 papers). Pascal Chastagner is often cited by papers focused on Glioma Diagnosis and Treatment (47 papers), Neuroblastoma Research and Treatments (47 papers) and Childhood Cancer Survivors' Quality of Life (34 papers). Pascal Chastagner collaborates with scholars based in France, United States and United Kingdom. Pascal Chastagner's co-authors include François Doz, Dominique Plantaz, C Kalifa, Didier Frappaz, Olivier Hartmann, Jean Michon, Nicolas Sirvent, Éric Bouffet, Carole Coze and H Rubie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Pascal Chastagner

155 papers receiving 3.4k citations

Peers

Countries citing papers authored by Pascal Chastagner

Since Specialization

Citations

This map shows the geographic impact of Pascal Chastagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Chastagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Chastagner more than expected).

Fields of papers citing papers by Pascal Chastagner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Chastagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Chastagner. The network helps show where Pascal Chastagner may publish in the future.

Co-authorship network of co-authors of Pascal Chastagner

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Chastagner. A scholar is included among the top collaborators of Pascal Chastagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Chastagner. Pascal Chastagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population 2024 ·Cancer Medicine ·(unknown), Pascal Auquier, Virginie Gandemer, Yves Bertrand, (unknown), (unknown), André Baruchel, (unknown), Jean‐Hugues Dalle, Pascal Chastagner, Justyna Kanold, Maryline Poirée, (unknown), (unknown), Isabelle Pellier, Gérard Michel, Julie Berbis	2
2	Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS 2024 ·European Journal of Cancer ·(unknown), (unknown), Nadège Corradini, Nicolás André, Estelle Thébaud, Marion Gambart, Anne Sophie Defachelles, Natacha Entz‐Werlé, Pascal Chastagner, Émilie De Carli, Stéphane Ducassou, Judith Landman‐Parker, Tiphaine Adam de Beaumais, (unknown), Stefan Michiels, Gilles Vassal, Dominique Valteau‐Couanet, Birgit Geoerger, (unknown)	1
3	Impact of childhood leukemia on siblings: their long-term perception of family functioning and its relationship with their psychosocial characteristics using structural equation modeling 2023 ·Journal of Cancer Survivorship ·(unknown), Pascal Auquier, Yves Bertrand, Marie‐Dominique Tabone, (unknown), André Baruchel, Virginie Gandemer, Jean‐Hugues Dalle, Pascal Chastagner, Justyna Kanold, Maryline Poirée, (unknown), Geneviève Plat, Isabelle Pellier, Gérard Michel, Julie Berbis	0
4	Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma 2023 ·International Journal of Nanomedicine ·Maxime Durand, (unknown), (unknown), Jérôme Devy, (unknown), Gautier Laurent, Rana Bazzi, Stéphane Roux, Nicolas Richet, (unknown), Pascal Chastagner, Sophie Pinel	18
5	Brothers and sisters of childhood acute leukemia survivors: Their long‐term quality of life and its determinants 2022 ·Cancer Medicine ·(unknown), Pascal Auquier, Zeinab Hamidou, Yves Bertrand, (unknown), (unknown), André Baruchel, Virginie Gandemer, Jean‐Hugues Dalle, Pascal Chastagner, Justyna Kanold, Maryline Poirée, Nicolas Sirvent, Geneviève Plat, Isabelle Pellier, Gérard Michel, Julie Berbis	4
6	Exploring heterogeneity of adrenal cortical tumors in children: The French pediatric rare tumor group (Fracture) experience 2019 ·Pediatric Blood & Cancer ·Cécile Picard, Cécile Faure‐Conter, Pierre Leblond, Laurence Brugières, Cécile Thomas‐Teinturier, Frédéric Hameury, Anne Sophie Defachelles, Arnauld Verschuur, Hervé J. Brisse, Sabine Sarnacki, Frédérique Dijoud, Yves Réguerre, Pascal Chastagner, Matthieu Carton, Daniel Orbach	13
7	NUT carcinoma in children and adults: A multicenter retrospective study 2017 ·Pediatric Blood & Cancer ·(unknown), Gaëlle Pierron, Paul Fréneaux, Sophie Huybrechts, (unknown), Dominique Plantaz, M. Juliéron, (unknown), Antoîne Italiano, Frédéric Millot, Christophe Le Tourneau, Guy Leverger, Pascal Chastagner, Matthieu Carton, Daniel Orbach	64
8	Nécessité d’une réflexion globale autour des thérapeutiques « personnalisées » proposées en oncologie pédiatrique 2017 ·Archives de Pédiatrie ·Pascal Chastagner	1
9	Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma 2012 ·Cancer Research ·Hana Janoušková, (unknown), David Y. Léger, (unknown), Fanny Noulet, Éric Guérin, Dominique Guénot, Sophie Pinel, Pascal Chastagner, François Plénat, (unknown), Jacqueline Lehmann‐Che, Julien Godet, Sophie Martin, Jan Teisinger, Monique Dontenwill	104
10	Successful management with clofarabine for refractory leukaemia in a young adult with chronic renal failure 2010 ·American Journal of Hematology ·(unknown), Antoine Kimmoun, Audrey Contet, Laurence Clément, Alexandra Salmon, Claudine Schmitt, Pascal Chastagner	2
11	Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours 2010 ·European Journal of Cancer ·Hervé Rubie, Birgit Geoerger, Didier Frappaz, Antonin Schmitt, Pierre Leblond, Anna Julienne Selbé Ndiaye, Isabelle Aerts, Marie‐Cécile Le Deley, Jean‐Claude Gentet, Angélo Paci, Pascal Chastagner, Nathalie Dias, (unknown), Marlène Pasquet, Étienne Chatelut, Judith Landman‐Parker, Nadège Corradini, Gilles Vassal	15
12	2007 Standards, Options, and Recommendations: Use of erythropoiesis‐stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer 2009 ·Pediatric Blood & Cancer ·Perrine Marec‐Bérard, Pascal Chastagner, Diana Kassab‐Chahmi, Nicole Casadevall, Christian Marchal, J.L. Misset, Isabelle Ray‐Coquard	8
13	Effect of adapted physical activity on health-related quality of life among hospitalized children and adolescents (the ACTIV'HOP randomized controlled trial): Design and methods 2009 ·Contemporary Clinical Trials ·Élodie Speyer, Anne Vuillemin, (unknown), Pascal Chastagner, Serge Briançon	10
14	[Cancer in children: epidemiologic, diagnostic and therapeutic characteristics]. 2008 ·PubMed ·Daniel Orbach, Pascal Chastagner, François Doz	0
15	Le pronostic du neuroblastome de l'enfant. Méthodes d'étude et utilisation en pratique clinique 2004 ·Archives de Pédiatrie ·Yves Pérel, Dominique Valteau‐Couanet, Jean Michon, F. Lavrand, Carole Coze, Christophe Bergeron, (unknown), Dominique Plantaz, Pascal Chastagner, Frédéric Bernard, Caroline Thomas, H Rubie	13
16	Treatment of stage 4s neuroblastoma – report of 10 years' experience of the French Society of Paediatric Oncology (SFOP) 2003 ·British Journal of Cancer ·(unknown), Gudrun Schleiermacher, H Rubie, Olivier Hartmann, Christophe Bergeron, Pascal Chastagner, Françoise Méchinaud, Jean Michon	68
17	Localised and unresectable neuroblastoma in infants: Excellent outcome with primary chemotherapy 2001 ·Medical and Pediatric Oncology ·H Rubie, Dominique Plantaz, Carole Coze, Jean Michon, Didier Frappaz, M.C. Baranzelli, Pascal Chastagner, (unknown), (unknown)	20
18	Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer 2000 ·Medical and Pediatric Oncology ·Pascal Chastagner, Emmanuel Plouvier, (unknown), Patrick Plésiat, Alain Lozniewski, D. Sommelet	15
19	N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. 1997 ·Journal of Clinical Oncology ·H Rubie, Olivier Hartmann, Jean Michon, Didier Frappaz, Carole Coze, Pascal Chastagner, M.C. Baranzelli, Dominique Plantaz, Hervé Avet‐Loiseau, Jean Bénard, Olivier Delattre, M Favrot, (unknown), Antoine Thyss, Yves Pérel, Christophe Bergeron, (unknown), J.P. Vannier, J Lemerle, D. Sommelet	148
20	Phase II study of ifosfamide in childhood brain tumors: A report by the French society of pediatric oncology (SFOP) 1993 ·Medical and Pediatric Oncology ·Pascal Chastagner, (unknown), C Kalifa, M Brunat-Mentigny, Jean‐Michel Zucker, François Deméocq, Marie‐Christine Baranzelli, Philippe Tron, Christophe Bergeron, F Pein, L. de Lumley	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact